Table IV.
Joint-effect analysis of PLCB1 and AFP for overall survival and recurrence-free survival.
| A, Overall survival | ||||||
|---|---|---|---|---|---|---|
| Group | AFP expression | PLCB1 expression | Events/total | MST (months) | Adjusted HR (95% CI) | Adjusted P-value |
| 1 | Low | Low | 18/68 | NA | Ref. | 0.008 |
| 2 | Low | High | 32/82 | NA | 2.162 (1.143–4.089) | 0.018 |
| High | Low | |||||
| 3 | High | High | 32/59 | 36.4 | 4.382 (1.703–11.276) | 0.002 |
| B, Recurrence-free survival | ||||||
| Group | AFP expression | PLCB1 expression | Events/total | MST (months) | Adjusted HR (95% CI) | Adjusted P-value |
| I | Low | Low | 29/68 | NA | Ref. | 0.075 |
| II | Low | High | 50/82 | 40.1 | 1.613 (1.019–2.555) | 0.041 |
| High | Low | |||||
| III | High | High | 37/59 | 23.0 | 1.670 (1.012–2.755) | 0.045 |
Group 1, AFP low expression and PLCB1 low expression; Group 2, AFP low expression and PLCB1 high expression, and AFP high expression and PLCB1 low expression; Group 3, AFP high expression and PLCB1 high expression; Group I, AFP low expression and PLCB1 low expression; Group II, AFP low expression and PLCB1 high expression, and AFP high expression and PLCB1 low expression; Group III, AFP high expression and PLCB1 high expression. Ref., reference value (1); PLCB, phospholipase B; AFP, α-fetoprotein; MST, median survival time; HR, hazard ratio; 95% CI, 95% confidence interval. Bold indicates significant P-values.